Abstract
A novel series of diaryl biuret derivatives containing a tetrazole moiety was designed and synthesized. All the target compounds were evaluated for their in vitro antitumor activity against HT-29, HepG2, MCF-7 and A549 cells by MTT assay. Most of them exhibited obvious antitumor activity, and four of them(4a, 4c, 4h and 7a) were superior to sorafenib in general. Among them, Compound 4h displayed more potent activity than sorafenib in all tested cancer cells. Compound 4c exhibited the most outstanding activity in inhibition of growth of HepG2 cells(IC50=0.55 μmol/L). Further, they both revealed favorable metabolic stability in in vitro assay. Compounds 4c and 4h are promising candidates for further development.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gild M. L., Bullock M., Robinson B. G., Cliftonbligh R., Nat. Rev. Endocrinol., 2011, 7(7), 617
Nagilla M., Brown R. L., Cohen E. E. W., Adv. Ther., 2012, 29(11), 925
Kataoka Y., Mukohara T., Tomioka H., Funakoshi Y., Kiyota N., Fujiwara Y., Yashiro M., Hirakawa K., Hirai M., Minami H., Invest. New Drug., 2012, 30, 1352
Okamoto K., Ikemorikawada M., Jestel A., Konig K., Funahashi Y., Matsushima T., Tsuruoka A., Inoue A., Matsui J., Acs Med. Chem. Lett., 2015, 6(1), 89
Bai X., Ma X., Xie X., Shao M., Guo N., Yan N., Yao L., Chem. J. Chinese Universities., 2017, 38(1), 47
Ma R., Chen J., Liang Y., Linb S., Zhub L., Liangb X., Caib X., Biomed. Pharmacother., 2017, 88, 459
Wilhelm S., Adnane L., Newell P., Villanueva A., Llovet J., Lynch M., Mol. Cancer Ther., 2008, 7, 3129
Copur M. S., Obermiller A., Clin. Colorectal Canc., 2011, 10(3), 151
Mattina J., Mackinnon N., Henderson V. C., Fergusson D., Kimmel-man J., Cancer Res., 2016, 76(16), 4627
Liu C., Chen Z., Chen Y., Lu J., Li Y., Wang S., Wu G., Qian F., Mol. Pharm., 2016, 13, 599
Jiang S., Qin Y., Wu S., Xu S., Li K., Yang P., Zhao K., Lin L., Gong J., J. Chem. Eng. Data, 2017, 62, 259
Temirak A., Abdulla M., Elhefnawi M., Anticancer Agents Med. Chem., 2012, 12, 1088
Liao J. J., J. Med. Chem., 2007, 38(22), 409
Lin X., Huang X. P., Chen G., Whaley R., Peng S., Wang Y., Zhang G., Wang S. X., Wang S., Roth B. L., Huang N., J. Med. Chem., 2012, 55(12), 5749
Wang Y., Qin M., Hu G., Wang T., Nie M., Wu D., Gong P., Chinese Journal of Medicinal Chemistry, 2014, 24(5), 345
Qin M., Liao W., Xu C., Fu B., Ren J., Gu Y., Gong P., Arch. Pharm., 2013, 346(11), 840
Khan A. A., Siddiqui N., Akhtar M. J., Ali Z., Yar M. S., Arch. Pharm., 2016, 349(4), 277
Pireddu R., Forinash K. D., Sun N. N., Martin M. P., Sung S. S., Alexander B., Zhu J. Y., Guida W. C., Schonbrunn E., Sebti S. M., Lawrence N. J., Medchemcomm., 2012, 3(6), 699
Fouladdel S., Khalaj A., Adibpour N., Azizi E., Bioorg. Med. Chem. Lett., 2010, 20(19), 5772
Cai W., Liu W., Xie Y., Wu J., Liu Y., Liu C., Xu W., Tang L., Wang J., Zhao G., Chem. Res. Chinese Universities, 2017, 33(1), 1
Yao P., Zhai X., Liu D., Qi B. H., Tan H. L., Jin Y. C., Gong P., Arch. Pharm., 2010, 343(1), 17
Wu H., Handoko, Raj M., Arora P. S., Org. Lett., 2017, 19(19), 5122
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supported by the National Natural Science Foundation of China(No.81502924).
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Tian, Y., Yu, S., Cai, L. et al. Synthesis and Antitumor Activity of Sorafenib Analogs Containing a Tetrazole Moiety. Chem. Res. Chin. Univ. 35, 41–46 (2019). https://doi.org/10.1007/s40242-018-8236-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40242-018-8236-5